T cell subsets and their signature cytokines in autoimmune and inflammatory diseases

Cytokine

Volumn 74, Issue 1, 2015, Pages 5-17

  Raphael, Itay ^a   Nalawade, Saisha ^a   Eagar, Todd N ^b   Forsthuber, Thomas G ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Autoimmune disease; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Signature cytokine; T cell subset

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HUMAN; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TH22 CELL; TH9 CELL; CD4+ T LYMPHOCYTE; IMMUNOLOGY; MULTIPLE SCLEROSIS;

AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84930178921     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.09.011     Document Type: Review

References (227)

1. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
2. Berger A. Th1 and Th2 responses: what are they?. BMJ 2000, 321:424.
3. Raphael I., Forsthuber T.G. Stability of T-cell lineages in autoimmune diseases. Expert Rev Clin Immunol 2012, 8:299-301. 10.1586/eci.12.22.
4. Skurkovich S., Skurkovich B. Anticytokine therapy, especially anti-interferon-gamma, as a pathogenetic treatment in TH-1 autoimmune diseases. Ann NY Acad Sci 2005, 684-700:1051. 10.1196/annals.1361.113.
5. Bosisio D., et al. Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood 2002, 99:3427-3431.
6. Peng S.L., Szabo S.J., Glimcher L.H. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci USA 2002, 99:5545-5550. 10.1073/pnas.082114899.
7. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu Rev Immunol 1997, 15:749-795. 10.1146/annurev.immunol.15.1.749.
8. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75:163-189. 10.1189/jlb.0603252.
9. Panitch H.S., Hirsch R.L., Schindler J., Johnson K.P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987, 37:1097-1102.
10. Olsson T. Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol 1992, 40:211-218.
11. Voskuhl R.R., et al. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 1993, 15:137-143.
12. McDonald A.H., Swanborg R.H. Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J Immunol 1988, 140:1132-1138.
13. Ando D.G., Clayton J., Kono D., Urban J.L., Sercarz E.E. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 1989, 124:132-143.
14. Szabo S.J., et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669.
15. Ji N., Sosa R.A., Forsthuber T.G. More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases. Immunotherapy 2011, 3:435-441. 10.2217/imt.10.111.
16. Hohnoki K., Inoue A., Koh C.S. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol 1998, 87:27-32.
17. Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1995, 144:245-268.
18. Prud'homme G.J., Kono D.H., Theofilopoulos A.N. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-1 and interferon-gamma mRNA in the lymph nodes of lupus-prone mice. Mol Immunol 1995, 32:495-503.
19. Balomenos D., Rumold R., Theofilopoulos A.N. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Investig 1998, 101:364-371. 10.1172/JCI750.
20. Schwarting A., Wada T., Kinoshita K., Tesch G., Kelley V.R. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol 1998, 161:494-503.
21. Haas C., Ryffel B., Le Hir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB×NZW)F1 mice. J Immunol 1998, 160:3713-3718.
22. Pollard K.M., Hultman P., Kono D.H. Immunology and genetics of induced systemic autoimmunity. Autoimmun Rev 2005, 4:282-288. 10.1016/j.autrev.2004.12.005.
23. Preble O.T., Black R.J., Friedman R.M., Klippel J.H., Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982, 216:429-431.
24. Wandl U.B., et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992, 65:70-74.
25. Machold K.P., Smolen J.S. Interferon-gamma induced exacerbation of systemic lupus erythematosus. J Rheumatol 1990, 17:831-832.
26. Ferber I.A., et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996, 156:5-7.
27. Willenborg D.O., Fordham S., Bernard C.C., Cowden W.B., Ramshaw I.A. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996, 157:3223-3227.
28. Flaishon L., et al. Cutting edge: anti-inflammatory properties of low levels of IFN-gamma. J Immunol 2002, 168:3707-3711.
29. Haskins K., McDuffie M. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 1990, 249:1433-1436.
30. Xu H., Rizzo L.V., Silver P.B., Caspi R.R. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis. Cell Immunol 1997, 178:69-78. 10.1006/cimm.1997.1121.
31. Refaeli Y., Van Parijs L., Alexander S.I., Abbas A.K. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 2002, 196:999-1005.
32. Bernabei P., et al. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol 2001, 70:950-960.
33. Curran T.A., Jalili R.B., Farrokhi A., Ghahary A. IDO expressing fibroblasts promote the expansion of antigen specific regulatory T cells. Immunobiology 2014, 219:17-24. 10.1016/j.imbio.2013.06.008.
34. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4:762-774. 10.1038/nri1457.
35. Komiyama Y., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:566-573.
36. Cruz A., et al. Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol 2006, 177:1416-1420.
37. Dardalhon V., Korn T., Kuchroo V.K., Anderson A.C. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008, 31:252-256. 10.1016/j.jaut.2008.04.017.
38. Wildbaum G., Zohar Y., Karin N. Antigen-specific CD25-Foxp3-FN-gamma(high) CD4+ T cells restrain the development of experimental allergic encephalomyelitis by suppressing Th17. Am J Pathol 2010, 176:2764-2775. 10.2353/ajpath.2010.090855.
39. Murugaiyan G., Beynon V. Pires Da Cunha, A., Joller, N. & Weiner, H. L. IFN-gamma limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol 2012, 189:5277-5283. 10.4049/jimmunol.1200808.
40. Wang Z., et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Investig 2006, 116:2434-2441. 10.1172/JCI25826.
41. Nishibori T., Tanabe Y., Su L., David M. Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J Exp Med 2004, 199:25-34. 10.1084/jem.20020509.
42. Nordmann A., Wixler L., Boergeling Y., Wixler V., Ludwig S. A new splice variant of the human guanylate-binding protein 3 mediates anti-influenza activity through inhibition of viral transcription and replication. FASEB J: Off Publ Fed Am Soc Exp Biol 2012, 26:1290-1300. 10.1096/fj.11-189886.
43. Lubeseder-Martellato C., et al. Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. Am J Pathol 2002, 161:1749-1759. 10.1016/S0002-9440(10)64452-5.
44. Forster F., et al. Guanylate binding protein 1-mediated interaction of T cell antigen receptor signaling with the cytoskeleton. J Immunol 2014, 192:771-781. 10.4049/jimmunol.1300377.
45. Zhou X., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009, 10:1000-1007. 10.1038/ni.1774.
46. Komatsu N., et al. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009, 106:1903-1908. 10.1073/pnas.0811556106.
47. Hirota K., et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011, 12:255-263. 10.1038/ni.1993.
48. Arnett H.A., et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001, 4:1116-1122. 10.1038/nn738.
49. Tsakiri N., Papadopoulos D., Denis M.C., Mitsikostas D.D., Kollias G. TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE. Eur J Immunol 2012, 42:403-412. 10.1002/eji.201141659.
50. Gomez D., et al. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?. Semin Arthritis Rheum 2004, 33:404-413.
51. Licona-Limon P., Kim L.K., Palm N.W., Flavell R.A. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013, 14:536-542. 10.1038/ni.2617.
52. Saenz S.A., Taylor B.C., Artis D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev 2008, 226:172-190. 10.1111/j.1600-065X.2008.00713.x.
53. Vahedi G., et al. Helper T-cell identity and evolution of differential transcriptomes and epigenomes. Immunol Rev 2013, 252:24-40. 10.1111/imr.12037.
54. Howard M., Paul W.E. Interleukins for B lymphocytes. Lymphokine Res 1982, 1:1-4.
55. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999, 17:701-738. 10.1146/annurev.immunol.17.1.701.
56. Vitetta E.S., et al. Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1. J Exp Med 1985, 162:1726-1731.
57. Coffman R.L., et al. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol 1986, 136:4538-4541.
58. Mantovani A., Biswas S.K., Galdiero M.R., Sica A., Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013, 229:176-185. 10.1002/path.4133.
59. Chen F., et al. An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection. Nat Med 2012, 18:260-266. 10.1038/nm.2628.
60. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007, 8:913-919. 10.1038/ni1507.
61. Hulshof S., Montagne L., De Groot C.J., Van Der Valk P. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 2002, 38:24-35.
62. Genain C.P., et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996, 274:2054-2057.
63. Antel J.P., Bar-Or A. Do myelin-directed antibodies predict multiple sclerosis?. N Engl J Med 2003, 349:107-109. 10.1056/NEJMp030098.
64. Iglesias A., Bauer J., Litzenburger T., Schubart A., Linington C. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 2001, 36:220-234.
65. Lafaille J.J., et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997, 186:307-312.
66. Jager A., Dardalhon V., Sobel R.A., Bettelli E., Kuchroo V.K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009, 183:7169-7177. 10.4049/jimmunol.0901906.
67. Hirahara K., et al. Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease. J Allergy Clin Immunol 2013, 131:1276-1287. 10.1016/j.jaci.2013.03.015.
68. Dean G.S., Tyrrell-Price J., Crawley E., Isenberg D.A. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000, 59:243-251.
69. Theofilopoulos A.N., Koundouris S., Kono D.H., Lawson B.R. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res 2001, 3:136-141.
70. Luzina I.G., et al. Vasculitis in the Palmerston North mouse model of lupus: phenotype and cytokine production profile of infiltrating cells. Arthritis Rheum 1999, 42:561-568. 10.1002/1529-0131(199904)42:3<561::AID-ANR22>3.0.CO;2-X.
71. Nakajima A., Hirose S., Yagita H., Okumura K. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol 1997, 158:1466-1472.
72. Bagenstose L.M., Salgame P., Monestier M. Mercury-induced autoimmunity in the absence of IL-4. Clin Exp Immunol 1998, 114:9-12.
73. Afanasyeva M., et al. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol 2001, 159:193-203. 10.1016/S0002-9440(10)61685-9.
74. Finkelman F.D., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990, 8:303-333. 10.1146/annurev.iy.08.040190.001511.
75. Swain S.L., Weinberg A.D., English M., Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990, 145:3796-3806.
76. Rocken M., Racke M., Shevach E.M. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol Today 1996, 17:225-231.
77. Heeger P.S., et al. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J Immunol 2000, 164:5771-5781.
78. Racke M.K., et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994, 180:1961-1966.
79. Kuchroo V.K., et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718.
80. Brocke S., et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996, 379:343-346. 10.1038/379343a0.
81. Broberg E.K., Salmi A.A., Hukkanen V. IL-4 is the key regulator in herpes simplex virus-based gene therapy of BALB/c experimental autoimmune encephalomyelitis. Neurosci Lett 2004, 364:173-178. 10.1016/j.neulet.2004.04.059.
82. Tran G.T., et al. IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity. Blood 2012, 119:4441-4450. 10.1182/blood-2011-12-396101.
83. O'Garra A., Steinman L., Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 1997, 9:872-883.
84. Rapoport M.J., et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993, 178:87-99.
85. Takatsu K., Tominaga A., Hamaoka T. Antigen-induced T cell-replacing factor (TRF). I. Functional characterization of a TRF-producing helper T cell subset and genetic studies on TRF production. J Immunol 1980, 124:2414-2422.
86. Zurawski G., de Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994, 15:19-26. 10.1016/0167-5699(94)90021-3.
87. Kuperman D.A., et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002, 8:885-889. 10.1038/nm734.
88. Bice J.B., Leechawengwongs E., Montanaro A. Biologic targeted therapy in allergic asthma. Ann Allergy Asthma Immunol: Off Publ Am College Allergy Asthma Immunol 2014, 112:108-115. 10.1016/j.anai.2013.12.013.
89. Martins T.B., et al. Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol 2011, 136:696-704. 10.1309/AJCP7UBK8IBVMVNR.
90. Weir C., Bernard C.C., Backstrom B.T. IL-5-deficient mice are susceptible to experimental autoimmune encephalomyelitis. Int Immunol 2003, 15:1283-1289.
91. Chen M., et al. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Multiple sclerosis 2001, 7:209-219.
92. Carneiro J.R., et al. IL-2, IL-5, TNF-alpha and IFN-gamma mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions. Clinics 2011, 66:77-82.
93. Wen X., et al. Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus. Eur J Immunol 2004, 34:2740-2749. 10.1002/eji.200425267.
94. Liu Y., et al. IL-13 induces connective tissue growth factor in rat hepatic stellate cells via TGF-beta-independent Smad signaling. J Immunol 2011, 187:2814-2823. 10.4049/jimmunol.1003260.
95. Cihakova D., et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol 2008, 172:1195-1208. 10.2353/ajpath.2008.070207.
96. Elnaggar R., et al. The effect of hydrodynamics-based delivery of an IL-13-Ig fusion gene for experimental autoimmune myocarditis in rats and its possible mechanism. Eur J Immunol 2005, 35:1995-2005. 10.1002/eji.200425776.
97. Kleinschek M.A., et al. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 2007, 204:161-170. 10.1084/jem.20061738.
98. Ochoa-Reparaz J., et al. IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen. J Immunol 2008, 181:954-968.
99. Ochi H., et al. Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J Neurol Sci 2002, 201:45-51.
100. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain: J Neurol 1997, 120(Pt 5):865-916.
101. Genain C.P., et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Investig 1995, 96:2966-2974. 10.1172/JCI118368.
102. Illera V.A., Perandones C.E., Stunz L.L., Mower D.A., Ashman R.F. Apoptosis in splenic B lymphocytes. Regulation by protein kinase C and IL-4. J Immunol 1993, 151:2965-2973.
103. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517. 10.1146/annurev.immunol.021908.132710.
104. Gu C., Wu L., Li X. IL-17 family: cytokines, receptors and signaling. Cytokine 2013, 64:477-485. 10.1016/j.cyto.2013.07.022.
105. Cua D.J., Tato C.M. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010, 10:479-489. 10.1038/nri2800.
106. Reynolds J.M., Angkasekwinai P., Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev 2010, 21:413-423. 10.1016/j.cytogfr.2010.10.002.
107. Cua D.J., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748. 10.1038/nature01355.
108. Langrish C.L., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240. 10.1084/jem.20041257.
109. Park H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141. 10.1038/ni1261.
110. Harrington L.E., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132. 10.1038/ni1254.
111. Fossiez F., et al. Interleukin-17. Int Rev Immunol 1998, 16:541-551.
112. Jovanovic D.V., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998, 160:3513-3521.
113. Zhu S., Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci 2012, 122:487-511. 10.1042/CS20110496.
114. Benedetti G., Miossec P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol 2014, 44:339-347. 10.1002/eji.201344184.
115. Lock C., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8:500-508. 10.1038/nm0502-500.
116. Kotake S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Investig 1999, 103:1345-1352. 10.1172/JCI5703.
117. Wong C.K., et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008, 127:385-393. 10.1016/j.clim.2008.01.019.
118. Doreau A., et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009, 10:778-785. 10.1038/ni.1741.
119. Linden A., Hoshino H., Laan M. Airway neutrophils and interleukin-17. Eur Respir J 2000, 15:973-977.
120. Hsu H.C., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008, 9:166-175. 10.1038/ni1552.
121. Hsu H.C., et al. Overexpression of activation-induced cytidine deaminase in B cells is associated with production of highly pathogenic autoantibodies. J Immunol 2007, 178:5357-5365.
122. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950. 10.1038/ni833.
123. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
124. Emamaullee J.A., et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009, 58:1302-1311. 10.2337/db08-1113.
125. Cai L., et al. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 2001, 16:10-21. 10.1006/cyto.2001.0939.
126. Shahrara S., Pickens S.R., Dorfleutner A., Pope R.M. IL-17 induces monocyte migration in rheumatoid arthritis. J Immunol 2009, 182:3884-3891. 10.4049/jimmunol.0802246.
127. Yang X.O., et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008, 205:1063-1075. 10.1084/jem.20071978.
128. Dogan R.N., Elhofy A., Karpus W.J. Production of CCL2 by central nervous system cells regulates development of murine experimental autoimmune encephalomyelitis through the recruitment of TNF- and iNOS-expressing macrophages and myeloid dendritic cells. J Immunol 2008, 180:7376-7384.
129. Roy M., Richard J.F., Dumas A., Vallieres L. CXCL1 can be regulated by IL-6 and promotes granulocyte adhesion to brain capillaries during bacterial toxin exposure and encephalomyelitis. J Neuroinflammation 2012, 9:18. 10.1186/1742-2094-9-18.
130. Ivanov I.I., et al. The orphan nuclear receptor RORgammaT directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133. 10.1016/j.cell.2006.07.035.
131. Kebir H., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007, 13:1173-1175. 10.1038/nm1651.
132. Ke Y., et al. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009, 182:3183-3190. 10.4049/jimmunol.0802487.
133. Zielinski C.E., et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012, 484:514-518. 10.1038/nature10957.
134. Xu J., et al. C-Maf regulates IL-10 expression during Th17 polarization. J Immunol 2009, 182:6226-6236. 10.4049/jimmunol.0900123.
135. Haak S., et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Investig 2009, 119:61-69. 10.1172/JCI35997.
136. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10:857-863. 10.1038/ni.1767.
137. Nograles K.E., et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009, 123:1244-1252. [e1242]. 10.1016/j.jaci.2009.03.04.
138. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009, 10:864-871. 10.1038/ni.1770.
139. Pestka S., et al. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979. 10.1146/annurev.immunol.22.012703.104622.
140. Kunz M., Ibrahim S.M. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm 2009, 2009:979258. 10.1155/2009/979258.
141. Tian T., Yu S., Ma D. Th22 and related cytokines in inflammatory and autoimmune diseases. Expert Opin Ther Targets 2013, 17:113-125. 10.1517/14728222.2013.736497.
142. Ikeuchi H., et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005, 52:1037-1046. 10.1002/art.20965.
143. Geboes L., et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 2009, 60:390-395. 10.1002/art.24220.
144. Kim K.W., et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum 2012, 64:1015-1023. 10.1002/art.33446.
145. Zhang L., et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One 2012, 7:e31000. 10.1371/journal.pone.0031000.
146. Zhang L., et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:606-614. 10.1007/s10875-011-9540-8.
147. Zhao L., et al. IL-22+ CD4+ T cells in patients with rheumatoid arthritis. Int J Rheum Dis 2013, 16:518-526. 10.1111/1756-185X.12099.
148. Beyeen A.D., et al. IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation. J Immunol 2010, 185:6883-6890. 10.4049/jimmunol.1001392.
149. Xu W., et al. IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2013, 261:87-91. 10.1016/j.jneuroim.2013.04.021.
150. Kreymborg K., et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007, 179:8098-8104.
151. Pan H.F., et al. Decreased serum IL-22 levels in patients with systemic lupus erythematosus. Clin Chim Acta; Int J Clin Chem 2009, 401:179-180. 10.1016/j.cca.2008.11.009.
152. Cheng F., Guo Z., Xu H., Yan D., Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009, 68:604-606. 10.1136/ard.2008.097089.
153. Qin W.Z., et al. Expressions of IL-22 in circulating CD4+/CD8+ T cells and their correlation with disease activity in SLE patients. Clin Exp Med 2011, 11:245-250. 10.1007/s10238-011-0134-9.
154. Lin J., Yue L.H., Chen W.Q. Decreased plasma IL-22 levels and correlations with IL-22-producing T helper cells in patients with new-onset systemic lupus erythematosus. Scand J Immunol 2014, 79:131-136. 10.1111/sji.12135.
155. Stange J., et al. IL-22 mediates host defense against an intestinal intracellular parasite in the absence of IFN-gamma at the cost of Th17-driven immunopathology. J Immunol 2012, 188:2410-2418. 10.4049/jimmunol.1102062.
156. Sonnenberg G.F., et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 2012, 336:1321-1325. 10.1126/science.1222551.
157. Bird L. Mucosal immunology: IL-22 keeps commensals in their place. Nat Rev Immunol 2012, 12:550-551. 10.1038/nri3263.
158. Zenewicz L.A., et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007, 27:647-659. 10.1016/j.immuni.2007.07.023.
159. Feng D., et al. Interleukin-22 ameliorates cerulein-induced pancreatitis in mice by inhibiting the autophagic pathway. Int J Biol Sci 2012, 8:249-257. 10.7150/ijbs.3967.
160. Yang X., Zheng S.G. Interleukin-22: a likely target for treatment of autoimmune diseases. Autoimmun Rev 2014, 13:615-620. 10.1016/j.autrev.2013.11.008.
161. Van Belle A.B., et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 2012, 188:462-469. 10.4049/jimmunol.1102224.
162. McCrirrick A., Hunter S. Pain on injection of propofol: the effect of injectate temperature. Anaesthesia 1990, 45:443-444.
163. Temann U.A., Ray P., Flavell R.A. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J Clin Investig 2002, 109:29-39. 10.1172/JCI13696.
164. Tan C., Gery I. The unique features of Th9 cells and their products. Crit Rev Immunol 2012, 32:1-10.
165. Zhao P., Xiao X., Ghobrial R.M., Li X.C. IL-9 and Th9 cells: progress and challenges. Int Immunol 2013, 25:547-551. 10.1093/intimm/dxt039.
166. Li H., Nourbakhsh B., Cullimore M., Zhang G.X., Rostami A. IL-9 is important for T-cell activation and differentiation in autoimmune inflammation of the central nervous system. Eur J Immunol 2011, 41:2197-2206. 10.1002/eji.201041125.
167. Leng R.X., Pan H.F., Ye D.Q., Xu Y. Potential roles of IL-9 in the pathogenesis of systemic lupus erythematosus. Am J Clin Exp Immunol 2012, 1:28-32.
168. Hiromura K., Kurosawa M., Yano S., Naruse T. Tubulointerstitial mast cell infiltration in glomerulonephritis. Am J Kidney Dis: Off J Natl Kidney Found 1998, 32:593-599.
169. Forbes E.E., et al. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med 2008, 205:897-913. 10.1084/jem.20071046.
170. Ouyang H., et al. Increased interleukin9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep 2013, 7:1031-1037. 10.3892/mmr.2013.1258.
171. Stassen M., Schmitt E., Bopp T. From interleukin-9 to T helper 9 cells. Ann NY Acad Sci 2012, 1247:56-68. 10.1111/j.1749-6632.2011.06351.x.
172. Gershon R.K., Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970, 18:723-737.
173. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
174. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061. 10.1126/science.1079490.
175. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336. 10.1038/ni904.
176. Workman C.J., Szymczak-Workman A.L., Collison L.W., Pillai M.R., Vignali D.A. The development and function of regulatory T cells. Cell Mol Life Sci: CMLS 2009, 66:2603-2622. 10.1007/s00018-009-0026-2.
177. Jonuleit H., Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003, 171:6323-6327.
178. Robinson D.S. Regulatory T cells and asthma. Clin Exp Allergy: J Br Soc Allergy Clin Immunol 2009, 39:1314-1323. 10.1111/j.1365-2222.2009.03301.x.
179. Costantino C.M., Baecher-Allan C., Hafler D.A. Multiple sclerosis and regulatory T cells. J Clin Immunol 2008, 28:697-706. 10.1007/s10875-008-9236-x.
180. Jaeckel E., Mpofu N., Saal N., Manns M.P. Role of regulatory T cells for the treatment of type 1 diabetes mellitus. Horm Metab Res=Hormon- und Stoffwechselforschung=Hormones et metabolisme 2008, 40:126-136. []. 10.1055/s-2008-104242.
181. Miyara M., Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007, 13:108-116. 10.1016/j.molmed.2007.01.003.
182. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998, 16:137-161. 10.1146/annurev.immunol.16.1.137.
183. Travis M.A., Sheppard D. TGF-beta activation and function in immunity. Annu Rev Immunol 2014, 32:51-82. 10.1146/annurev-immunol-032713-120257.
184. Carrier Y., Yuan J., Kuchroo V.K., Weiner H.L. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J Immunol 2007, 178:179-185.
185. Marie J.C., Letterio J.J., Gavin M., Rudensky A.Y. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005, 201:1061-1067. 10.1084/jem.20042276.
186. Pyzik M., Piccirillo C.A. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukoc Biol 2007, 82:335-346. 10.1189/jlb.1006644.
187. Awasthi A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007, 8:1380-1389. 10.1038/ni1541.
188. Chen M.L., Yan B.S., Bando Y., Kuchroo V.K., Weiner H.L. Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol 2008, 180:7327-7337.
189. McGeachy M.J., Stephens L.A., Anderton S.M. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 2005, 175:3025-3032.
190. Zhang X., et al. Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. Int Immunol 2006, 18:495-503. 10.1093/intimm/dxh390.
191. You S., et al. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci USA 2007, 104:6335-6340. 10.1073/pnas.0701171104.
192. You S., et al. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann NY Acad Sci 2008, 1150:300-310. 10.1196/annals.1447.046.
193. Ouyang W., Rutz S., Crellin N.K., Valdez P.A., Hymowitz S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011, 29:71-109. 10.1146/annurev-immunol-031210-101312.
194. Groux H., et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742. 10.1038/39614.
195. Wildbaum G., Netzer N., Karin N. Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading. J Clin Investig 2002, 110:701-710. 10.1172/JCI15176.
196. de Waal Malefyt R., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991, 174:915-924.
197. Ding L., Linsley P.S., Huang L.Y., Germain R.N., Shevach E.M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993, 151:1224-1234.
198. Speiran K., et al. Endogenous suppression of mast cell development and survival by IL-4 and IL-10. J Leukoc Biol 2009, 85:826-836. 10.1189/jlb.0708448.
199. Williams L.M., Ricchetti G., Sarma U., Smallie T., Foxwell B.M. Interleukin-10 suppression of myeloid cell activation - a continuing puzzle. Immunology 2004, 113:281-292. 10.1111/j.1365-2567.2004.01988.x.
200. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
201. Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999, 190:995-1004.
202. Zhang X., et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol 2004, 16:249-256.
203. Spach K.M., Nashold F.E., Dittel B.N., Hayes C.E. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:6030-6037.
204. Kearley J., Barker J.E., Robinson D.S., Lloyd C.M. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med 2005, 202:1539-1547. 10.1084/jem.20051166.
205. Meiler F., Klunker S., Zimmermann M., Akdis C.A., Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008, 63:1455-1463. 10.1111/j.1398-9995.2008.01774.x.
206. Burdin N., et al. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol 1995, 154:2533-2544.
207. Rousset F., et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992, 89:1890-1893.
208. Saeland S., Duvert V., Moreau I., Banchereau J. Human B cell precursors proliferate and express CD23 after CD40 ligation. J Exp Med 1993, 178:113-120.
209. Go N.F., et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990, 172:1625-1631.
210. van der Neut Kolfschoten M., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557. 10.1126/science.114460.
211. Veldhoen M., Hocking R.J., Flavell R.A., Stockinger B. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol 2006, 7:1151-1156. 10.1038/ni1391.
212. Dardalhon V., et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008, 9:1347-1355. 10.1038/ni.1677.
213. Veldhoen M., et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008, 9:1341-1346. 10.1038/ni.1659.
214. Filippi C.M., et al. Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes 2008, 57:2684-2692. 10.2337/db08-0609.
215. Hatton R.D. TGF-beta in Th17 cell development: the truth is out there. Immunity 2011, 34:288-290. 10.1016/j.immuni.2011.03.009.
216. Nakayamada S., Takahashi H., Kanno Y., O'Shea J.J. Helper T cell diversity and plasticity. Curr Opin Immunol 2012, 24:297-302. 10.1016/j.coi.2012.01.014.
217. O'Shea J.J., Paul W.E. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010, 327:1098-1102. 10.1126/science.1178334.
218. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010, 28:445-489. 10.1146/annurev-immunol-030409-101212.
219. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278:1910-1914. 10.1074/jbc.M207577200.
220. Codarri L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011, 12:560-567. 10.1038/ni.2027.
221. El-Behi M., et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 2011, 12:568-575. 10.1038/ni.2031.
222. Ponomarev E.D., et al. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 2007, 178:39-48.
223. Noster R., et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Translational Med 2014, 6:241ra280. 10.1126/scitranslmed.300870.
224. Basu R., Hatton R.D., Weaver C.T. The Th17 family: flexibility follows function. Immunol Rev 2013, 252:89-103. 10.1111/imr.12035.
225. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001, 19:163-196. 10.1146/annurev.immunol.19.1.163.
226. Cleynen I., Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012, 9:496-503. 10.1038/nrgastro.2012.125.
227. Forsthuber T.G., Ji N. Quo vadis Th1 and Th2 cells in autoimmunity and infectious diseases: Th17 cells, the new kid on the block. Expert Rev Clin Immunol 2007, 3:251-254. 10.1586/1744666X.3.3.251.